Table 4.
Prognostic factors analysis of 5-year PFS
| Parameter | Univariate
|
Multivariate
|
|
|---|---|---|---|
| P-value | P-value | RR (95% CI) | |
| Age (≤60 years) | <0.001 | <0.001 | 3.568 (2.113–6.023) |
| ECOG scores (<2) | <0.001 | 0.001 | 3.088 (1.615–5.904) |
| HDAC6 high expression | 0.012 | 0.012 | 0.510 (0.301–0.864) |
| Ann Arbor staging | <0.001 | <0.001 | 3.456 (2.012–5.938) |
| R-CHOP | 0.001 | 0.003 | 0.400 (0.219–0.730) |
| Increased LDH | 0.245 | ||
| GCB | 0.057 | ||
Abbreviations: HDAC6, histone deacetylase 6; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; GCB, germinal center B-cell-like; CHOP, cyclophosphamide, doxorubicine, vincristine, prednisone; R-CHOP, rituximab plus CHOP; RR, rate ratios.